10x Genomics, INC 8-K filings

10x Genomics stockholders re-elected three Class I directors and ratified the appointment of Ernst & Young LLP at the 2026 Annual Meeting.

10x Genomics reported Q1 2026 results with a 3% revenue decrease year-over-year, but excluding one-time items, revenue grew 9%, driven by new product launches and strategic partnerships.

10x Genomics reported significantly reduced net and operating losses for Q4 and full year 2025, alongside a strong cash position and new strategic partnerships, while forecasting modest revenue growth for 2026.

10x Genomics announced preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025, showing mixed growth across its single cell and spatial biology segments.

10x Genomics announced the retirement of its Chief Legal Officer, Eric S. Whitaker, effective January 1, 2026, with Dr. Randy Wu appointed as his successor.

10x Genomics reported a 2% sequential revenue increase excluding one-time items, alongside a significant boost in cash and cash equivalents for Q3 2025, despite a year-over-year revenue decline.

10x Genomics reported a significant turnaround in Q2 2025 financial performance, driven by a patent litigation settlement and improved gross margins, despite a slight decrease in core revenue.

10x Genomics, Inc. announced the successful re-election of two Class III directors, the ratification of Ernst & Young LLP as its independent auditor, and the advisory approval of executive compensation at its annual stockholders' meeting held on June 3, 2025.

10x Genomics resolves all outstanding litigation with Bruker Corporation, resulting in a $68 million settlement and future royalty payments.

10x Genomics announced its Q1 2025 financial results, featuring revenue growth boosted by a patent settlement, alongside cost-cutting measures including a workforce reduction due to uncertainty in research funding.

10x Genomics reported a decrease in revenue for both Q4 and full year 2024, while launching the Billion Cells Project and providing a modest revenue growth outlook for 2025.

10x Genomics reported preliminary unaudited results for Q4 and full year 2024, highlighting sequential revenue growth but a year-over-year decrease in some areas.

10x Genomics reported a slight revenue decrease in Q3 2024, alongside an improved gross margin and reduced operating expenses, while also lowering its full-year revenue guidance.

10x Genomics reported preliminary third-quarter revenue of $151.7 million, a 1% decrease year-over-year, with significant declines in instrument sales offset by growth in consumables and services.

10x Genomics reported a 4% revenue increase for Q2 2024, a CFO transition, and a new Chief Commercial Officer.

10x Genomics has appointed Dr. Sarah A. Teichmann, a prominent figure in genomics and computational biology, to its Board of Directors, effective immediately.

10x Genomics has appointed Alan V. Mateo, a seasoned life sciences executive, to its Board of Directors, effective immediately.

10x Genomics held its annual meeting on June 11, 2024, where stockholders elected a director, ratified the appointment of an auditor, and voted on other proposals.

10x Genomics announced a 5% year-over-year revenue increase for the first quarter of 2024, reaching $141 million, primarily fueled by growth in its Spatial product line.

10x Genomics announced a 20% revenue increase for 2023 and provided a 2024 revenue growth outlook of 8% to 12%.

10x Genomics' Chief Commercial Officer, James Wilbur, will depart the company on February 1, 2024, with a severance package.